Strategies to select the best pharmacophore model: a case study in pyrazoloquinazoline class of PLK-1 inhibitors
- 12 September 2017
- journal article
- research article
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 27 (1) , 234-260
Abstract
No abstract availableKeywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology (DBT (BT/PR14373/MED/30/530/2010))
This publication has 34 references indexed in Scilit:
- A combined approach based on 3D pharmacophore and docking for identification of new aurora A kinase inhibitorsMedicinal Chemistry Research, 2013
- Identification of novel, potent and selective inhibitors of Polo-like kinase 1Bioorganic & Medicinal Chemistry Letters, 2012
- 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitorsBioorganic & Medicinal Chemistry Letters, 2010
- Identification of 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazoline Derivatives as a New Class of Orally and Selective Polo-Like Kinase 1 InhibitorsJournal of Medicinal Chemistry, 2010
- Novel Approach for Efficient Pharmacophore-Based Virtual Screening: Method and ApplicationsJournal of Chemical Information and Modeling, 2009
- Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- Structure of the Catalytic Domain of Human Polo-like Kinase 1,Biochemistry, 2007